Industry Research Reports
Home > Reports > Medical Devices & Consumables > Global Kidney Cancer Diagnosis Market Outlook, In‑Depth Analysis & Forecast to 2031
Global Kidney Cancer Diagnosis Market Outlook, In‑Depth Analysis & Forecast to 2031
Industry: Medical Devices & Consumables
Published Date: 2025-11-02
Pages: 132 Pages
Report ld: 5346833
Request Sample
Customized Report
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
Kidney Cancer Diagnosis Market Size(US$)
CAGR 2025-2031
5.0%
Market Size,2031
USD 750
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 559 million
Market Forecast in 2031(Value)
US$ 750 million
CAGR
5.0%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global Kidney Cancer Diagnosis market is projected to grow from US$ 535 million in 2024 to US$ 750 million by 2031, at a CAGR of 5.0% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Includes:
This definitive report equips business leaders, decision-makers and stakeholders with a 360° view of the global Kidney Cancer Diagnosis market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region's dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
MARKET SEGMENTATION
By Company
- Myriad Genetics Inc.
- NeoGenomics Laboratories
- Thermo Fisher Scientific Inc.
- Sysmex Corporation
- Rosetta Genomics
- Illumina Inc.
- Abbott Laboratories
- Roche Holding AG
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- Immunohistochemical Test
- Complete Blood Count Test
- Urine Test
- Blood Chemistry Test
Segment by Application
- Hospital
- Surgery Center
CHAPTER OUTLINE
Chapter 1: Defines the Kidney Cancer Diagnosis study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; top manufactures 2024 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments.
Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 15: Actionable conclusions and strategic recommendations.
WHY THIS REPORT
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYRESEARCH'S STRENGTHS
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
TABLE OF CONTENTS
1 Study Coverage
1.1 Introduction to Kidney Cancer Diagnosis: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Kidney Cancer Diagnosis Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Immunohistochemical Test
1.2.3 Complete Blood Count Test
1.2.4 Urine Test
1.2.5 Blood Chemistry Test
1.3 Market Segmentation by Application
1.3.1 Global Kidney Cancer Diagnosis Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Surgery Center
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Kidney Cancer Diagnosis Revenue Estimates and Forecasts 2020-2031
2.2 Global Kidney Cancer Diagnosis Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Kidney Cancer Diagnosis Sales Estimates and Forecasts 2020-2031
2.4 Global Kidney Cancer Diagnosis Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Kidney Cancer Diagnosis Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Kidney Cancer Diagnosis Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 Immunohistochemical Test Market Size by Manufacturers
3.5.2 Complete Blood Count Test Market Size by Manufacturers
3.5.3 Urine Test Market Size by Manufacturers
3.5.4 Blood Chemistry Test Market Size by Manufacturers
3.6 Global Kidney Cancer Diagnosis Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Kidney Cancer Diagnosis Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Kidney Cancer Diagnosis Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Kidney Cancer Diagnosis Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Kidney Cancer Diagnosis Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Kidney Cancer Diagnosis Sales and Revenue by Type (2020-2031)
6.4 North America Kidney Cancer Diagnosis Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Kidney Cancer Diagnosis Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Kidney Cancer Diagnosis Sales and Revenue by Type (2020-2031)
7.4 Europe Kidney Cancer Diagnosis Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Kidney Cancer Diagnosis Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Kidney Cancer Diagnosis Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Kidney Cancer Diagnosis Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Kidney Cancer Diagnosis Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Kidney Cancer Diagnosis Sales and Revenue by Type (2020-2031)
9.4 Central and South America Kidney Cancer Diagnosis Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Kidney Cancer Diagnosis Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Kidney Cancer Diagnosis Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Kidney Cancer Diagnosis Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Kidney Cancer Diagnosis Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Myriad Genetics Inc.
11.1.1 Myriad Genetics Inc. Corporation Information
11.1.2 Myriad Genetics Inc. Business Overview
11.1.3 Myriad Genetics Inc. Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.1.4 Myriad Genetics Inc. Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Myriad Genetics Inc. Kidney Cancer Diagnosis Sales by Product in 2024
11.1.6 Myriad Genetics Inc. Kidney Cancer Diagnosis Sales by Application in 2024
11.1.7 Myriad Genetics Inc. Kidney Cancer Diagnosis Sales by Geographic Area in 2024
11.1.8 Myriad Genetics Inc. Kidney Cancer Diagnosis SWOT Analysis
11.1.9 Myriad Genetics Inc. Recent Developments
11.2 NeoGenomics Laboratories
11.2.1 NeoGenomics Laboratories Corporation Information
11.2.2 NeoGenomics Laboratories Business Overview
11.2.3 NeoGenomics Laboratories Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.2.4 NeoGenomics Laboratories Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 NeoGenomics Laboratories Kidney Cancer Diagnosis Sales by Product in 2024
11.2.6 NeoGenomics Laboratories Kidney Cancer Diagnosis Sales by Application in 2024
11.2.7 NeoGenomics Laboratories Kidney Cancer Diagnosis Sales by Geographic Area in 2024
11.2.8 NeoGenomics Laboratories Kidney Cancer Diagnosis SWOT Analysis
11.2.9 NeoGenomics Laboratories Recent Developments
11.3 Thermo Fisher Scientific Inc.
11.3.1 Thermo Fisher Scientific Inc. Corporation Information
11.3.2 Thermo Fisher Scientific Inc. Business Overview
11.3.3 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.3.4 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.3.5 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis Sales by Product in 2024
11.3.6 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis Sales by Application in 2024
11.3.7 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis Sales by Geographic Area in 2024
11.3.8 Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis SWOT Analysis
11.3.9 Thermo Fisher Scientific Inc. Recent Developments
11.4 Sysmex Corporation
11.4.1 Sysmex Corporation Corporation Information
11.4.2 Sysmex Corporation Business Overview
11.4.3 Sysmex Corporation Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.4.4 Sysmex Corporation Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.4.5 Sysmex Corporation Kidney Cancer Diagnosis Sales by Product in 2024
11.4.6 Sysmex Corporation Kidney Cancer Diagnosis Sales by Application in 2024
11.4.7 Sysmex Corporation Kidney Cancer Diagnosis Sales by Geographic Area in 2024
11.4.8 Sysmex Corporation Kidney Cancer Diagnosis SWOT Analysis
11.4.9 Sysmex Corporation Recent Developments
11.5 Rosetta Genomics
11.5.1 Rosetta Genomics Corporation Information
11.5.2 Rosetta Genomics Business Overview
11.5.3 Rosetta Genomics Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.5.4 Rosetta Genomics Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.5.5 Rosetta Genomics Kidney Cancer Diagnosis Sales by Product in 2024
11.5.6 Rosetta Genomics Kidney Cancer Diagnosis Sales by Application in 2024
11.5.7 Rosetta Genomics Kidney Cancer Diagnosis Sales by Geographic Area in 2024
11.5.8 Rosetta Genomics Kidney Cancer Diagnosis SWOT Analysis
11.5.9 Rosetta Genomics Recent Developments
11.6 Illumina Inc.
11.6.1 Illumina Inc. Corporation Information
11.6.2 Illumina Inc. Business Overview
11.6.3 Illumina Inc. Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.6.4 Illumina Inc. Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.6.5 Illumina Inc. Recent Developments
11.7 Abbott Laboratories
11.7.1 Abbott Laboratories Corporation Information
11.7.2 Abbott Laboratories Business Overview
11.7.3 Abbott Laboratories Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.7.4 Abbott Laboratories Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.7.5 Abbott Laboratories Recent Developments
11.8 Roche Holding AG
11.8.1 Roche Holding AG Corporation Information
11.8.2 Roche Holding AG Business Overview
11.8.3 Roche Holding AG Kidney Cancer Diagnosis Product Models, Descriptions and Specifications
11.8.4 Roche Holding AG Kidney Cancer Diagnosis Sales, Price, Revenue and Gross Margin (2020-2025)
11.8.5 Roche Holding AG Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Kidney Cancer Diagnosis Industry Chain
12.2 Kidney Cancer Diagnosis Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Kidney Cancer Diagnosis Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Kidney Cancer Diagnosis Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Kidney Cancer Diagnosis Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Kidney Cancer Diagnosis Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
TABLE OF FIGURES
List of Tables
Table 1. Global Kidney Cancer Diagnosis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global Kidney Cancer Diagnosis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global Kidney Cancer Diagnosis Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global Kidney Cancer Diagnosis Revenue by Region (2026-2031) & (US$ Million)
Table 6. Global Kidney Cancer Diagnosis Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
Table 7. Global Kidney Cancer Diagnosis Sales by Region (2020-2025) & (K Units)
Table 8. Global Kidney Cancer Diagnosis Sales by Region (2026-2031) & (K Units)
Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 10. Global Kidney Cancer Diagnosis Sales by Manufacturers (2020-2025) & (K Units)
Table 11. Global Kidney Cancer Diagnosis Sales Share by Manufacturers (2020-2025)
Table 12. Global Kidney Cancer Diagnosis Revenue by Manufacturers (2020-2025) & (US$ Million)
Table 13. Global Kidney Cancer Diagnosis Revenue Market Share by Manufacturers (2020-2025)
Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 15. Global Kidney Cancer Diagnosis by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Diagnosis as of 2024)
Table 16. Global Kidney Cancer Diagnosis Average Gross Margin (%) by Manufacturer (2020 VS 2024)
Table 17. Global Kidney Cancer Diagnosis Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
Table 18. Key Manufacturers Kidney Cancer Diagnosis Manufacturing Base and Headquarters
Table 19. Global Kidney Cancer Diagnosis Market Concentration Ratio (CR5 and HHI)
Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 22. Global Kidney Cancer Diagnosis Sales by Type (2020-2025) & (K Units)
Table 23. Global Kidney Cancer Diagnosis Sales by Type (2026-2031) & (K Units)
Table 24. Global Kidney Cancer Diagnosis Revenue by Type (2020-2025) & (US$ Million)
Table 25. Global Kidney Cancer Diagnosis Revenue by Type (2026-2031) & (US$ Million)
Table 26. Global Kidney Cancer Diagnosis ASP by Type (2020-2031) & (US$/Unit)
Table 27. Technical Specifications by Key Product Type
Table 28. Global Kidney Cancer Diagnosis Sales by Application (2020-2025) & (K Units)
Table 29. Global Kidney Cancer Diagnosis Sales by Application (2026-2031) & (K Units)
Table 30. Kidney Cancer Diagnosis High-Growth Sectors Demand CAGR (2024-2031)
Table 31. Global Kidney Cancer Diagnosis Revenue by Application (2020-2025) & (US$ Million)
Table 32. Global Kidney Cancer Diagnosis Revenue by Application (2026-2031) & (US$ Million)
Table 33. Global Kidney Cancer Diagnosis ASP by Application (2020-2031) & (US$/Unit)
Table 34. Top Customers by Region
Table 35. Top Customers by Application
Table 36. North America Kidney Cancer Diagnosis Growth Accelerators and Market Barriers
Table 37. North America Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 38. North America Kidney Cancer Diagnosis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 39. Europe Kidney Cancer Diagnosis Growth Accelerators and Market Barriers
Table 40. Europe Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 41. Europe Kidney Cancer Diagnosis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 42. Asia-Pacific Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 43. Asia-Pacific Kidney Cancer Diagnosis Sales (K Units) by Country (2020 VS 2024 VS 2031)
Table 44. Asia-Pacific Kidney Cancer Diagnosis Growth Accelerators and Market Barriers
Table 45. Southeast Asia Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 46. Central and South America Kidney Cancer Diagnosis Investment Opportunities and Key Challenges
Table 47. Central and South America Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 48. Middle East and Africa Kidney Cancer Diagnosis Investment Opportunities and Key Challenges
Table 49. Middle East and Africa Kidney Cancer Diagnosis Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 50. Myriad Genetics Inc. Corporation Information
Table 51. Myriad Genetics Inc. Description and Major Businesses
Table 52. Myriad Genetics Inc. Product Models, Descriptions and Specifications
Table 53. Myriad Genetics Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 54. Myriad Genetics Inc. Sales Value Proportion by Product in 2024
Table 55. Myriad Genetics Inc. Sales Value Proportion by Application in 2024
Table 56. Myriad Genetics Inc. Sales Value Proportion by Geographic Area in 2024
Table 57. Myriad Genetics Inc. Kidney Cancer Diagnosis SWOT Analysis
Table 58. Myriad Genetics Inc. Recent Developments
Table 59. NeoGenomics Laboratories Corporation Information
Table 60. NeoGenomics Laboratories Description and Major Businesses
Table 61. NeoGenomics Laboratories Product Models, Descriptions and Specifications
Table 62. NeoGenomics Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 63. NeoGenomics Laboratories Sales Value Proportion by Product in 2024
Table 64. NeoGenomics Laboratories Sales Value Proportion by Application in 2024
Table 65. NeoGenomics Laboratories Sales Value Proportion by Geographic Area in 2024
Table 66. NeoGenomics Laboratories Kidney Cancer Diagnosis SWOT Analysis
Table 67. NeoGenomics Laboratories Recent Developments
Table 68. Thermo Fisher Scientific Inc. Corporation Information
Table 69. Thermo Fisher Scientific Inc. Description and Major Businesses
Table 70. Thermo Fisher Scientific Inc. Product Models, Descriptions and Specifications
Table 71. Thermo Fisher Scientific Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Thermo Fisher Scientific Inc. Sales Value Proportion by Product in 2024
Table 73. Thermo Fisher Scientific Inc. Sales Value Proportion by Application in 2024
Table 74. Thermo Fisher Scientific Inc. Sales Value Proportion by Geographic Area in 2024
Table 75. Thermo Fisher Scientific Inc. Kidney Cancer Diagnosis SWOT Analysis
Table 76. Thermo Fisher Scientific Inc. Recent Developments
Table 77. Sysmex Corporation Corporation Information
Table 78. Sysmex Corporation Description and Major Businesses
Table 79. Sysmex Corporation Product Models, Descriptions and Specifications
Table 80. Sysmex Corporation Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 81. Sysmex Corporation Sales Value Proportion by Product in 2024
Table 82. Sysmex Corporation Sales Value Proportion by Application in 2024
Table 83. Sysmex Corporation Sales Value Proportion by Geographic Area in 2024
Table 84. Sysmex Corporation Kidney Cancer Diagnosis SWOT Analysis
Table 85. Sysmex Corporation Recent Developments
Table 86. Rosetta Genomics Corporation Information
Table 87. Rosetta Genomics Description and Major Businesses
Table 88. Rosetta Genomics Product Models, Descriptions and Specifications
Table 89. Rosetta Genomics Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 90. Rosetta Genomics Sales Value Proportion by Product in 2024
Table 91. Rosetta Genomics Sales Value Proportion by Application in 2024
Table 92. Rosetta Genomics Sales Value Proportion by Geographic Area in 2024
Table 93. Rosetta Genomics Kidney Cancer Diagnosis SWOT Analysis
Table 94. Rosetta Genomics Recent Developments
Table 95. Illumina Inc. Corporation Information
Table 96. Illumina Inc. Description and Major Businesses
Table 97. Illumina Inc. Product Models, Descriptions and Specifications
Table 98. Illumina Inc. Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 99. Illumina Inc. Recent Developments
Table 100. Abbott Laboratories Corporation Information
Table 101. Abbott Laboratories Description and Major Businesses
Table 102. Abbott Laboratories Product Models, Descriptions and Specifications
Table 103. Abbott Laboratories Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Abbott Laboratories Recent Developments
Table 105. Roche Holding AG Corporation Information
Table 106. Roche Holding AG Description and Major Businesses
Table 107. Roche Holding AG Product Models, Descriptions and Specifications
Table 108. Roche Holding AG Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 109. Roche Holding AG Recent Developments
Table 110. Key Raw Materials Distribution
Table 111. Raw Materials Key Suppliers
Table 112. Critical Raw Material Supplier Concentration (2024) & Risk Index
Table 113. Milestones in Production Technology Evolution
Table 114. Distributors List
Table 115. Market Trends and Market Evolution
Table 116. Market Drivers and Opportunities
Table 117. Market Challenges, Risks, and Restraints
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Kidney Cancer Diagnosis Product Picture
Figure 2. Global Kidney Cancer Diagnosis Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. Immunohistochemical Test Product Picture
Figure 4. Complete Blood Count Test Product Picture
Figure 5. Urine Test Product Picture
Figure 6. Blood Chemistry Test Product Picture
Figure 7. Global Kidney Cancer Diagnosis Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 8. Hospital
Figure 9. Surgery Center
Figure 10. Kidney Cancer Diagnosis Report Years Considered
Figure 11. Global Kidney Cancer Diagnosis Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 12. Global Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 13. Global Kidney Cancer Diagnosis Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 14. Global Kidney Cancer Diagnosis Revenue Market Share by Region (2020-2031)
Figure 15. Global Kidney Cancer Diagnosis Sales (2020-2031) & (K Units)
Figure 16. Global Kidney Cancer Diagnosis Sales (CAGR) by Region (2020-2031) (K Units)
Figure 17. Global Kidney Cancer Diagnosis Sales Market Share by Region (2020-2031)
Figure 18. Top 5 and Top 10 Manufacturers Kidney Cancer Diagnosis Sales Volume Market Share in 2024
Figure 19. Global Kidney Cancer Diagnosis Revenue Market Share Ranking (2024)
Figure 20. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 21. Immunohistochemical Test Revenue Market Share by Manufacturer in 2024
Figure 22. Complete Blood Count Test Revenue Market Share by Manufacturer in 2024
Figure 23. Urine Test Revenue Market Share by Manufacturer in 2024
Figure 24. Blood Chemistry Test Revenue Market Share by Manufacturer in 2024
Figure 25. Global Kidney Cancer Diagnosis Sales Market Share by Type (2020-2031)
Figure 26. Global Kidney Cancer Diagnosis Revenue Market Share by Type (2020-2031)
Figure 27. Global Kidney Cancer Diagnosis Sales Market Share by Application (2020-2031)
Figure 28. Global Kidney Cancer Diagnosis Revenue Market Share by Application (2020-2031)
Figure 29. North America Kidney Cancer Diagnosis Sales YoY (2020-2031) & (K Units)
Figure 30. North America Kidney Cancer Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 31. North America Top 5 Manufacturers Kidney Cancer Diagnosis Sales Revenue (US$ Million) in 2024
Figure 32. North America Kidney Cancer Diagnosis Sales Volume (K Units) by Type (2020- 2031)
Figure 33. North America Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Type (2020 - 2031)
Figure 34. North America Kidney Cancer Diagnosis Sales Volume (K Units) by Application (2020-2031)
Figure 35. North America Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 36. US Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 37. Canada Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 38. Mexico Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 39. Europe Kidney Cancer Diagnosis Sales YoY (2020-2031) & (K Units)
Figure 40. Europe Kidney Cancer Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 41. Europe Top 5 Manufacturers Kidney Cancer Diagnosis Sales Revenue (US$ Million) in 2024
Figure 42. Europe Kidney Cancer Diagnosis Sales Volume (K Units) by Type (2020-2031)
Figure 43. Europe Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 44. Europe Kidney Cancer Diagnosis Sales Volume (K Units) by Application (2020-2031)
Figure 45. Europe Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 46. Germany Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 47. France Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 48. U.K. Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 49. Italy Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 50. Russia Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 51. Asia-Pacific Kidney Cancer Diagnosis Sales YoY (2020-2031) & (K Units)
Figure 52. Asia-Pacific Kidney Cancer Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 53. Asia-Pacific Top 8 Manufacturers Kidney Cancer Diagnosis Sales Revenue (US$ Million) in 2024
Figure 54. Asia-Pacific Kidney Cancer Diagnosis Sales Volume (K Units) by Type (2020- 2031)
Figure 55. Asia-Pacific Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Type (2020- 2031)
Figure 56. Asia-Pacific Kidney Cancer Diagnosis Sales Volume (K Units) by Application (2020-2031)
Figure 57. Asia-Pacific Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 58. Indonesia Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 59. Japan Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 60. South Korea Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 61. China Taiwan Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 62. India Kidney Cancer Diagnosis Revenue (2020-2031) & (US$ Million)
Figure 63. Central and South America Kidney Cancer Diagnosis Sales YoY (2020-2031) & (K Units)
Figure 64. Central and South America Kidney Cancer Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 65. Central and South America Top 5 Manufacturers Kidney Cancer Diagnosis Sales Revenue (US$ Million) in 2024
Figure 66. Central and South America Kidney Cancer Diagnosis Sales Volume (K Units) by Type (2021-2031)
Figure 67. Central and South America Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 68. Central and South America Kidney Cancer Diagnosis Sales Volume (K Units) by Application (2020-2031)
Figure 69. Central and South America Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 70. Brazil Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 71. Argentina Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 72. Middle East, and Africa Kidney Cancer Diagnosis Sales YoY (2020-2031) & (K Units)
Figure 73. Middle East and Africa Kidney Cancer Diagnosis Revenue YoY (2020-2031) & (US$ Million)
Figure 74. Middle East and Africa Top 5 Manufacturers Kidney Cancer Diagnosis Sales Revenue (US$ Million) in 2024
Figure 75. Middle East and Africa Kidney Cancer Diagnosis Sales Volume (K Units) by Type (2021-2031)
Figure 76. South America Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Type (2020-2031)
Figure 77. Middle East and Africa Kidney Cancer Diagnosis Sales Volume (K Units) by Application (2020-2031)
Figure 78. Middle East and Africa Kidney Cancer Diagnosis Sales Revenue (US$ Million) by Application (2020-2031)
Figure 79. GCC Countries Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 80. Turkey Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 81. Egypt Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 82. South Africa Kidney Cancer Diagnosis Revenue (2020-2025) & (US$ Million)
Figure 83. Kidney Cancer Diagnosis Industry Chain Mapping
Figure 84. Regional Kidney Cancer Diagnosis Manufacturing Base Distribution (%)
Figure 85. Global Kidney Cancer Diagnosis Production Market Share by Region (2020-2031)
Figure 86. Kidney Cancer Diagnosis Production Process
Figure 87. Regional Kidney Cancer Diagnosis Production Cost Structure
Figure 88. Channels of Distribution (Direct Vs Distribution)
Figure 89. Bottom-up and Top-down Approaches for This Report
Figure 90. Data Triangulation
Figure 91. Key Executives Interviewed
KEY QUESTIONS ADDRESSED BY THE REPORT
What was the global market size of Kidney Cancer Diagnosis in 2025?
The global market size of Kidney Cancer Diagnosis in 2025 was 559 Million USD.
Which companies rank high in the global Kidney Cancer Diagnosis market?
What was the global market size of Kidney Cancer Diagnosis in 2031?
What is the annual compound growth rate of the global Kidney Cancer Diagnosis market size from 2025 to 2031?
Which region is expected to have the highest market share?
Related Reports
Kidney Cancer Diagnosis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Kidney Cancer Diagnosis was estimated to be worth US$ 559 million in 2025 and is projected to reach US$ 784 million, growing at a CAGR of 5.0% from 2026 to 2032.
Published Date: 2026-06-16
Pages: 131
USD 3950.00
(Single User License)
Global Kidney Cancer Diagnosis Market Research Report 2026
The global Kidney Cancer Diagnosis market was valued at US$ 559 million in 2025 and is anticipated to reach US$ 784 million by 2032, at a CAGR of 5.0% from 2026 to 2032.
Published Date: 2026-04-17
Pages: 112
USD 2900.00
(Single User License)
Global Kidney Cancer Diagnosis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Kidney Cancer Diagnosis market size was US$ 535 million in 2024 and is forecast to a readjusted size of US$ 750 million by 2031 with a CAGR of 5.0% during the forecast period 2025-2031.
Published Date: 2025-11-02
Pages: 78
USD 4250.00
(Single User License)
Kidney Cancer Diagnosis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Kidney Cancer Diagnosis was estimated to be worth US$ 535 million in 2024 and is forecast to a readjusted size of US$ 750 million by 2031 with a CAGR of 5.0% during the forecast period 2025-2031.
Published Date: 2025-01-13
Pages: 99
USD 3950.00
(Single User License)
Global Kidney Cancer Diagnosis Market Research Report 2025
The global market for Kidney Cancer Diagnosis was valued at US$ 535 million in the year 2024 and is projected to reach a revised size of US$ 750 million by 2031, growing at a CAGR of 5.0% during the forecast period.
Published Date: 2025-01-13
Pages: 78
USD 2900.00
(Single User License)
Global Kidney Cancer Diagnosis Market Research Report 2024
The global Kidney Cancer Diagnosis market was valued at US$ 465.5 million in 2023 and is anticipated to reach US$ 686.6 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
Published Date: 2024-01-12
Pages: 83
USD 2900.00
(Single User License)
Kidney Cancer Diagnosis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for Kidney Cancer Diagnosis was estimated to be worth US$ 559 million in 2025 and is projected to reach US$ 784 million, growing at a CAGR of 5.0% from 2026 to 2032.
Published: 2026-06-16
Pages: 131
USD 3950.00 (Single User License)Global Kidney Cancer Diagnosis Market Research Report 2026
The global Kidney Cancer Diagnosis market was valued at US$ 559 million in 2025 and is anticipated to reach US$ 784 million by 2032, at a CAGR of 5.0% from 2026 to 2032.
Published: 2026-04-17
Pages: 112
USD 2900.00 (Single User License)Global Kidney Cancer Diagnosis Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global Kidney Cancer Diagnosis market size was US$ 535 million in 2024 and is forecast to a readjusted size of US$ 750 million by 2031 with a CAGR of 5.0% during the forecast period 2025-2031.
Published: 2025-11-02
Pages: 78
USD 4250.00 (Single User License)Kidney Cancer Diagnosis- Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for Kidney Cancer Diagnosis was estimated to be worth US$ 535 million in 2024 and is forecast to a readjusted size of US$ 750 million by 2031 with a CAGR of 5.0% during the forecast period 2025-2031.
Published: 2025-01-13
Pages: 99
USD 3950.00 (Single User License)Global Kidney Cancer Diagnosis Market Research Report 2025
The global market for Kidney Cancer Diagnosis was valued at US$ 535 million in the year 2024 and is projected to reach a revised size of US$ 750 million by 2031, growing at a CAGR of 5.0% during the forecast period.
Published: 2025-01-13
Pages: 78
USD 2900.00 (Single User License)Global Kidney Cancer Diagnosis Market Research Report 2024
The global Kidney Cancer Diagnosis market was valued at US$ 465.5 million in 2023 and is anticipated to reach US$ 686.6 million by 2030, witnessing a CAGR of 5.0% during the forecast period 2024-2030.
Published: 2024-01-12
Pages: 83
USD 2900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
DESCRIPTION
OVERVIEW
MARKET SEGMENTATION
CHAPTER OUTLINE
WHY THIS REPORT
QYRESEARCH'S STRENGTHS
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
INTEREST IN THIS REPORT?
Get A Free Sample
Request For Quotation
OR
NEED A CUSTOMIZED REPORT?
Customized Report
Request Sample
Pre-Order Enquiry
Add to Cart
Buy Now